Delving into the Latest Updates on AstraZeneca R&D Mölndal with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

L-type calcium channel x Nav1.5 x hERG	1

关联

1

项与 AstraZeneca R&D Mölndal 相关的药物

AZD-1305

靶点

L-type calcium channel x Nav1.5 x hERG

作用机制

L-type calcium channel阻滞剂 [+2]

在研机构

AstraZeneca R&D Mölndal [+1]

原研机构

阿斯利康制药有限公司

在研适应症

心房颤动

非在研适应症

心房扑动 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 AstraZeneca R&D Mölndal 相关的临床结果

登录后查看更多信息

0 项与 AstraZeneca R&D Mölndal 相关的专利（医药）

登录后查看更多信息

36

项与 AstraZeneca R&D Mölndal 相关的文献（医药）

2015-03-10·Lakartidningen

Järntillskott rekommenderas vid renal anemi.

Review

作者: Stefansson, Bergur

The main causes for renal anemia are insufficient erythropoietin production and absolute and/or functional iron deficiency. Absolute iron deficiency occurs with blood losses (most common are gastro-intestinal bleedings and hemodialysis treatments) or inadequate iron absorption in the gut (mainly due to increased circulating hepcidin or treatment with erythropoiesis stimulating agents). The explanation for functional iron deficiency is the high level of circulating hepcidin found in chronic kidney disease patients. The transmembrane iron transporter ferroportin is internalized and degraded by hepcidin with subsequent decreased iron absorption from the gut and reduced mobilization from iron storing cells. Thus, the bioavailability of iron is decreased despite normal or high total iron content. The diagnosis of iron deficiency in chronic kidney disease can be problematic because inflammation is common, leading to false high circulating ferritin and false low transferrin saturation. Treatment with iron is recommended in chronic kidney disease patients to prevent or minimize anemia symptoms or to reduce the need for treatment with erythropoiesis stimulating agents or blood transfusions. Intravenous iron is recommended in patients on dialysis treatment but in non-dialysis patients, a 1-3 month trial of oral iron can be tried. However, this is seldom sufficient in patients treated with erythropoiesis stimulating agents.

2011-03-25·Proceedings of the 1st International Workshop on Linked Web Data Management

Linked data, an opportunity to mitigate complexity pharmaceutical research and development

作者: Andersson, Bo ; Forsberg, Kerstin

In the paper we present opportunities and challenges in applying linked data principles to improve the research utility of data to mitigate complexity in pharmaceutical research and development. Association and interpretation of the data needed for research and development in a pharmaceutical company has become a too complex task for individual scientists, or even teams to handle. Scientists need data to be organized for associations, prepared for not yet defined use and ready for automation where computers can work alongside the scientists.

2004-07-01·Journal of Chromatography A2区 · 化学

Packed column supercritical fluid chromatography of a peroxysome proliferator-activating receptor agonist drug

2区 · 化学

Article

作者: Gyllenhaal, Olle

This paper describes packed column supercritical fluid chromatography (SFC) for the analysis of a peroxysome proliferator-activating gamma-receptor agonist that is a carboxylic acid. Evaluation of conditions for the separation of this candidate drug and related compounds in bulk substance is described. A Chiralcel OD column was used for this purpose due to its high selective retention of related substances and relative inertness, though the enantioselectivity was negligible, with methanol as polar modifier. A high enantioselectivity was obtained on Chiralpak AD and it was possible to determine the enantiomeric purity within 10 min on a 5 cm short column. Both the achiral and the chiral systems were run without acid additive in the mobile phase and the level of detection of impurities by area was about 0.1%. For the analysis of samples dissolved in water, without any isolation step, 2-propanol was used as modifier. Due to the column surface activity, evidently generated by injected water, citric acid 1 mM was included as additive in the 2-propanol in order to maintain symmetric and undistorted peak shape. The detection limit for the assay was 21 microg mL(-1) (50 nmol mL(-1)) for 5 microL injected (R.S.D. 6.4%, n = 8). A 5 cm short Chiralcel OD column was used. Determination of enantiomeric purity of the drug in aqueous samples required increased sensitivity. The sample was acidified and extracted into a small volume of 1-pentanol, out of which 25 microl was analyzed by SFC. The minor enantiomer at the 3% (w/w) level added could be confirmed. Its ratio remained constant during the procedure as measured relative to a reference solution in organic media.

100 项与 AstraZeneca R&D Mölndal 相关的药物交易

登录后查看更多信息

100 项与 AstraZeneca R&D Mölndal 相关的转化医学

登录后查看更多信息